Preparation and in vitro evaluation of imiquimod loaded polylactide-based micelles as potential vaccine adjuvants

Pharmaceutical Research

Volumn 32, Issue 1, 2015, Pages 311-320

  Jiménez Sánchez, Gloria ^a   Pavot, Vincent ^a   Chane Haong, Christelle ^a   Handké, Nadège ^b   Terrat, Céline ^a   Gigmes, Didier ^b   Trimaille, Thomas ^b   Verrier, Bernard ^a  

^a UNIVERSITÉ LYON 1   (France)

^b AIX MARSEILLE UNIV   (France)

Author keywords

dendritic cell maturation; imiquimod; immunostimulation; polylactide based micelles; vaccine

Indexed keywords

AMINE; ANTIGEN P24; COPOLYMER; GAG PROTEIN; IMIQUIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE; POLY(LACTIDE) B POLY(N ACRYLOXYSUCCINIMIDE CO N VINYLPYRROLIDONE); POLYLACTIDE; TOLL LIKE RECEPTOR 7; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; AMINOQUINOLINE DERIVATIVE; DRUG CARRIER; IMMUNOLOGICAL ADJUVANT; MICELLE; POLY(LACTIDE)-B-POLY(N-ACRYLOXYSUCCINIMIDE-CO-N-VINYLPYRROLIDONE); POLYESTER; POVIDONE; VACCINE;

ANIMAL CELL; ARTICLE; CELL MATURATION; CELL SURFACE; CONTROLLED STUDY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; FLOW CYTOMETRY; GENE CONSTRUCT; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOSTIMULATION; IN VITRO STUDY; INCUBATION TIME; MACROPHAGE; MICELLE; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; CHEMISTRY; DRUG RELEASE; IMMUNOLOGY; METABOLISM; PARTICLE SIZE; SURFACE PROPERTY;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; CELL LINE; DENDRITIC CELLS; DRUG CARRIERS; DRUG LIBERATION; FLOW CYTOMETRY; HIV CORE PROTEIN P24; HUMANS; MACROPHAGES; MICE; MICELLES; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PARTICLE SIZE; POLYESTERS; POVIDONE; SURFACE PROPERTIES; VACCINES;

EID: 84922073722     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1465-5     Document Type: Article

References (36)

1. Alving CR, Peachman KK, Rao M, Reed SG. Adjuvants for human vaccines. Curr Opin Immunol. 2012;24:310-5.
2. Kool M, Fierens K, Lambrecht BN. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol. 2012;61:927-34.
3. Gregoriadis G, McCormack B, Obrenovic M, Saffie R, Zadi B, Perrie Y. Liposomes as immunological adjuvants and vaccine carriers. Methods. 1999;19:156-62.
4. Fox CB, Haensler J. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccine. 2013;12:747-58.
5. Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, Ficht TA. Polymeric particles in vaccine delivery. Curr Opin Microbiol. 2010;13:106-12.
6. Kasturi SP, Skountzou J, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 2011;470:543-50.
7. Pavot V, Rochereau N, Primard C, Genin C, Perouzel E, Lioux T, et al. Encapsulation of Nod1 and Nod2 receptor ligands into poly(lactic acid) nanoparticles potentiates their immune properties. J Control Release. 2013;167:60-7.
8. Guillon C, Mayol K, Terrat C, Compagnon C, Primard C, Charles MH, et al. Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. Vaccine. 2007;25:7491-501.
9. Ataman-Onal Y, Munier S, Ganée A, Terrat C, Durand PY, Battail N, et al. Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. J Control Release. 2006;112:175-85.
10. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11:373-84.
11. Geddes K, Magalhães JG, Girardin S. Unleashing the therapeutic potential of NOD-like receptors. Nat Rev Drug Discov. 2009;8:465-79.
12. Reddy ST, Swartz MA, Hubbell JA. Targeting dendritic cells with biomaterials. Trends Immunol. 2006;27:573-9.
13. Kazzaz J, Singh M, Ugozzoli M, Chesko J, Soenawan E, O'Hagan DT. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J Control Release. 2006;110:566-73.
14. Hafner AM, Corthésy B, Merkle HP. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant. Adv Drug Deliv Rev. 2013;65:1386-99.
15. Schlosser E, Mueller M, Fischer S, Basta S, Busch DH, Gander B, et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine. 2008;26:1626-37.
16. Fievez V, Plapied L, des Rieux A, Pourcelle V, Freichels H, Wascotte V, et al. Tarteting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur J Pharm Biopharm. 2009;73:16-24.
17. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas Jr JM. Treatment of genital warts with an immune response. J Am Acad Dermatol. 1998;38:230-9.
18. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999;21:1-14.
19. Larange A, Antonios D, Pallardy M, Kerdine-Romer S. TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation. J Leukoc Biol. 2009;85:673-83.
20. Bachelder EM, Beaudette TT, Broaders KE, Frechet JM, Albrecht MT, Mateczun AJ, et al. In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants. Mol Pharm. 2010;7:826-35.
21. Handké N, Lahaye V, Bertin D, Delair T, Verrier B, Gigmes D, et al. Elaboration of glycopolymer-functionalized micelles from an N-vinylpyrrolidone/lactide-based reactive copolymer platform. Macromol Biosci. 2013;13:1213-20.
22. Handké N, Ficheux D, Rollet M, Delair T, Mabrouk K, Bertin D, et al. Lysine-tagged peptide coupling onto polylactide nanoparticles coated with activated ester-based amphiphilic copolymer: a route to highly peptide-functionalized biodegradable carriers. Colloids Surf B: Biointerfaces. 2013;103:298-303.
23. Le Garrec D, Gori S, Luo L, Lessard D, Smith DC, Yessine MA, et al. Poly(N-vinylpyrrolidone)-block-poly(D, L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. J Control Release. 2004;99:83-101.
24. Gaucher G, Asahina K, Wang J, Leroux JC. Effect of poly(N-vinyl-pyrrolidone)-block-poly(D, L-lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles. Biomacromolecules. 2009;10:408-16.
25. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release. 2006;112:26-34.
26. Reddy ST, van der Vlies AJ, Simeoni E, Angeli V, Randolph GJ, O'Neil CP, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol. 2007;25:1159-64.
27. Eby JK, Dane KY, O'Neil CP, Hirosue S, Swartz MA, Hubbell JA. Polymer micelles with pyridyl disulfide-coupled antigen travel through lymphatics and show enhanced cellular responses following immunization. Acta Biomater. 2012;8:3210-7.
28. Tong J, Luxenhofer R, Yi X, Jordan R, Kabanov AV. Protein modification with amphiphilic block copoly(2-oxazoline)s as a new platform for enhanced cellular delivery. Mol Pharm. 2010;7:984-92.
29. Heffernan MJ, Murthy N. Disulfide-crosslinked polyion micelles for delivery of protein therapeutics. Ann Biomed Eng. 2009;37:1993-2002.
30. Hong L, Jinzhi L. Scaling law for the radius of gyration of proteins and its dependence on hydrophobicity. J Polym Sci B Polym Phys. 2009;47:207-14.
31. Schon MP, Schon M. Imiquimod: mode of action. Br J Dermatol. 2007;157:8-13.
32. Zhu KJ, Cen JP, Lou JX, Wang Q, Zhang X, Xu Y, et al. Imiquimod inhibits the differentiation but enhances the maturation of human monocyte-derived dendritic cells. Int Immunopharmacol. 2009;9:412-7.
33. Burns RP, Ferbel B, Tomai M, Miller R, Gaspari AA. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal langerhans' cells. Clin Immunol. 2000;94:13-23.
34. Wischke C, Zimmermann J, Wessinger B, Schendler A, Borchert HH, Peters JH, et al. Poly(I:C) coated PLGA microparticles induce dendritic cell maturation. Int J Pharm. 2009;365:61-8.
35. Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind G, Fokkink RG, et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood. 2011;118:6836-44.
36. Wischke C, Mathew S, Roch T, Frentsch M, Lendlein A. Potential of NOD receptor ligands as immunomodulators in particulate vaccine carriers. J Control Release. 2012;164:299-306.